Among these, the PI3K/AKT/mTOR pathway has been reported to be aberrantly activated in almost 80% glioma cases (Cancer Genome Atlas Research Network, 2008; Cheng et al., 2009). This evidence concerns the gene MTOR and central nervous system cancer.